Literature DB >> 6126499

Compliance to therapy in patients on a maintenance dose of sulfasalazine.

P A van Hees, J H van Tongeren.   

Abstract

In patients with inflammatory bowel disease using a maintenance dose of sulfasalazine (SASP), compliance to therapy was studied by measuring serum sulfapyridine (SP) levels. Serum SP levels were determined in 51 patients both during hospitalization and at outpatient follow-up 1-6 months later. In 21 patients (41.2%) the serum SP level was considerably lower at outpatient follow-up than the serum level before discharge. In 21 (12%) of 175 outpatients taking a maintenance dose of SASP, SP in serum was not detectable at all at repeated determination during follow-up. These results indicate that a substantial number of patients on maintenance therapy with SASP do not take the prescribed dose. Drug trials in these patients should therefore incorporate methods of detecting defaulters.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126499     DOI: 10.1097/00004836-198208000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  14 in total

1.  A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.

Authors:  Ali Keshavarzian; Lloyd Mayer; Bruce Salzberg; Michael Garone; Warren Finkelstein; Joseph Cappa; Myron Brand; Jon Hain; David Zelinger; Ronald Hegedus; Robert H Diamond; Ulka Campbell; Christi Lane; Paul Stang; John Watson; Fabio Cominelli
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

2.  Overcoming adherence issues in ulcerative colitis.

Authors:  Sunanda V Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-10

Review 3.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

4.  Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.

Authors:  Sunanda V Kane; Michael Sumner; Dory Solomon; Matthew Jenkins
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

5.  Self-reported treatment adherence in inflammatory bowel disease in Indian patients.

Authors:  Jay Bhatt; Samir Patil; Anand Joshi; Philip Abraham; Devendra Desai
Journal:  Indian J Gastroenterol       Date:  2009-11-24

Review 6.  Strategies to improve adherence and outcomes in patients with ulcerative colitis.

Authors:  Sunanda V Kane
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Microscopic activity in ulcerative colitis: what does it mean?

Authors:  S A Riley; V Mani; M J Goodman; S Dutt; M E Herd
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

8.  Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey.

Authors:  Stefan Schreiber; Julián Panés; Edouard Louis; Derek Holley; Mandy Buch; Kristine Paridaens
Journal:  BMC Gastroenterol       Date:  2012-08-15       Impact factor: 3.067

9.  Medication-taking behavior in a cohort of patients with inflammatory bowel disease.

Authors:  Isabel Bernal; Eugeni Domènech; Esther Garcia-Planella; Laura Marín; Míriam Mañosa; Mercè Navarro; Eduard Cabré; Miquel A Gassull
Journal:  Dig Dis Sci       Date:  2006-11-04       Impact factor: 3.487

Review 10.  Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.

Authors:  Lilliana Oliveira; Russell D Cohen
Journal:  Drug Des Devel Ther       Date:  2011-02-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.